optimal first-line treatment of chronic phase cmlicksh.org/2018/data/es02-1_kyoung_ha_kim.pdf ·...
TRANSCRIPT
![Page 1: Optimal first-line treatment of chronic phase CMLicksh.org/2018/data/ES02-1_Kyoung_Ha_Kim.pdf · Published clinical studies of TKI discontinuation in patients with CP-CML ASH 2017#](https://reader035.vdocuments.site/reader035/viewer/2022070822/5f25e48d3be37644733aac27/html5/thumbnails/1.jpg)
Optimal first-line treatment of chronic phase CML
순천향대학교병원
김 경 하
![Page 2: Optimal first-line treatment of chronic phase CMLicksh.org/2018/data/ES02-1_Kyoung_Ha_Kim.pdf · Published clinical studies of TKI discontinuation in patients with CP-CML ASH 2017#](https://reader035.vdocuments.site/reader035/viewer/2022070822/5f25e48d3be37644733aac27/html5/thumbnails/2.jpg)
** Frontline approval of bosutinib on December 2017
Baccarni et al., Blood 2013;122:872-84. Courtesy of Dr DK Kim
Advances in CML treatment, particularly regarding TKI, mandate
regular updating of concepts and management
![Page 3: Optimal first-line treatment of chronic phase CMLicksh.org/2018/data/ES02-1_Kyoung_Ha_Kim.pdf · Published clinical studies of TKI discontinuation in patients with CP-CML ASH 2017#](https://reader035.vdocuments.site/reader035/viewer/2022070822/5f25e48d3be37644733aac27/html5/thumbnails/3.jpg)
Response Criteria in CML
100%
10%
1%
0.1%
0.01%
0.001%
Diagnostic
1 log reduction
2 log reduction
3 log reduction
4 log reduction
5 log reduction
4.5 log reduction
~ MCyR (≤ 35% Ph+ in BM), 2nd line
~ CCyR (0% Ph+ in BM), Front line
MMR or MR3.0, Front line
MR4.0 (most reliable deep response)
MR5.0 or CMR
MR4.5, reliable parameter for CMR 0.0032%
International scale Log scale Definition of Response
![Page 4: Optimal first-line treatment of chronic phase CMLicksh.org/2018/data/ES02-1_Kyoung_Ha_Kim.pdf · Published clinical studies of TKI discontinuation in patients with CP-CML ASH 2017#](https://reader035.vdocuments.site/reader035/viewer/2022070822/5f25e48d3be37644733aac27/html5/thumbnails/4.jpg)
• Imatinib
• Dasatinib
• Nilotinib
• Bosutinib
• Radotinib
Frontline treatment options
![Page 5: Optimal first-line treatment of chronic phase CMLicksh.org/2018/data/ES02-1_Kyoung_Ha_Kim.pdf · Published clinical studies of TKI discontinuation in patients with CP-CML ASH 2017#](https://reader035.vdocuments.site/reader035/viewer/2022070822/5f25e48d3be37644733aac27/html5/thumbnails/5.jpg)
Selecting a frontline treatment
• Efficacy of TKI in first-line clinical trials
• Patient’s age
• Patient’s comorbidities
• TKI toxicity profile
• Adherence
• Risk score
• BCR-ABL transcript type
• Additional chromosomal abnormalities (ACAs)
![Page 6: Optimal first-line treatment of chronic phase CMLicksh.org/2018/data/ES02-1_Kyoung_Ha_Kim.pdf · Published clinical studies of TKI discontinuation in patients with CP-CML ASH 2017#](https://reader035.vdocuments.site/reader035/viewer/2022070822/5f25e48d3be37644733aac27/html5/thumbnails/6.jpg)
Pro
bab
ility
of
surv
ival
Time from onset of imatinib therapy (years)
BCR-ABL/ABL<9.8% OS= 93.3%
BCR-ABL/ABL>9.8% OS= 56.9%
p<0.0001
Survival According to MR at 3 months: 282 Patients Treated with Imatinib 1st-line
Marin D, et al. J Clin Oncol 2012;30(3):232-8.
Individualized TKI selection - Efficacy
10%
![Page 7: Optimal first-line treatment of chronic phase CMLicksh.org/2018/data/ES02-1_Kyoung_Ha_Kim.pdf · Published clinical studies of TKI discontinuation in patients with CP-CML ASH 2017#](https://reader035.vdocuments.site/reader035/viewer/2022070822/5f25e48d3be37644733aac27/html5/thumbnails/7.jpg)
CMR according to the BCR-ABL transcript level at 3 months
BCR-ABL/ABL≤0.61% (n=57), CMR = 84.7%
BCR-ABL/ABL>0.61% (n=222), CMR of 1.5%
p<0.0001
Individualized TKI selection - Efficacy
Inci
de
nce
of
CM
R
Marin D, et al. J Clin Oncol 2012;30(3):232-8.
Time from onset of imatinib therapy (years)
1%
![Page 8: Optimal first-line treatment of chronic phase CMLicksh.org/2018/data/ES02-1_Kyoung_Ha_Kim.pdf · Published clinical studies of TKI discontinuation in patients with CP-CML ASH 2017#](https://reader035.vdocuments.site/reader035/viewer/2022070822/5f25e48d3be37644733aac27/html5/thumbnails/8.jpg)
Summary of pivotal phase III trials of approved TKI for
the frontline treatment of CML
Jabbour and Kantarjian. Am J Hematol 2018;93:442-59
![Page 9: Optimal first-line treatment of chronic phase CMLicksh.org/2018/data/ES02-1_Kyoung_Ha_Kim.pdf · Published clinical studies of TKI discontinuation in patients with CP-CML ASH 2017#](https://reader035.vdocuments.site/reader035/viewer/2022070822/5f25e48d3be37644733aac27/html5/thumbnails/9.jpg)
High-dose imatinib and imatinib based
combinations : CML-study IV (10yr survival results)
Hehlmann et al. Leukemia 2017;31:2398-406
ASH 2017 # 897
Overall survival
![Page 10: Optimal first-line treatment of chronic phase CMLicksh.org/2018/data/ES02-1_Kyoung_Ha_Kim.pdf · Published clinical studies of TKI discontinuation in patients with CP-CML ASH 2017#](https://reader035.vdocuments.site/reader035/viewer/2022070822/5f25e48d3be37644733aac27/html5/thumbnails/10.jpg)
Multivariate analysis for impact on survival (n= 1252)
Hehlmann et al. Leukemia 2017;31:2398-406
ASH 2017 # 897
Conclusions
- IM 400 mg monotherapy provides close to normal life expectancy
- Survival between IM400mg and any experimental arm was not different
![Page 11: Optimal first-line treatment of chronic phase CMLicksh.org/2018/data/ES02-1_Kyoung_Ha_Kim.pdf · Published clinical studies of TKI discontinuation in patients with CP-CML ASH 2017#](https://reader035.vdocuments.site/reader035/viewer/2022070822/5f25e48d3be37644733aac27/html5/thumbnails/11.jpg)
DASISION 5 yr follow-up:
Cumulative MMR/ MR 4.5 rates over time
Cortes, et al. J Clin Oncol 2016;34:2333-40
![Page 12: Optimal first-line treatment of chronic phase CMLicksh.org/2018/data/ES02-1_Kyoung_Ha_Kim.pdf · Published clinical studies of TKI discontinuation in patients with CP-CML ASH 2017#](https://reader035.vdocuments.site/reader035/viewer/2022070822/5f25e48d3be37644733aac27/html5/thumbnails/12.jpg)
ENESTnd 5 yr follow-up:
Cumulative MR 4.5 rates over time
A Hochhaus, et al. Leukemia 2016;30:1044-54
![Page 13: Optimal first-line treatment of chronic phase CMLicksh.org/2018/data/ES02-1_Kyoung_Ha_Kim.pdf · Published clinical studies of TKI discontinuation in patients with CP-CML ASH 2017#](https://reader035.vdocuments.site/reader035/viewer/2022070822/5f25e48d3be37644733aac27/html5/thumbnails/13.jpg)
Takahashi, et al. Cancer 2016;122:3336-43
Propensity score matching analysis of dasatinib and
nilotinib as a frontline therapy with CML-CP
![Page 14: Optimal first-line treatment of chronic phase CMLicksh.org/2018/data/ES02-1_Kyoung_Ha_Kim.pdf · Published clinical studies of TKI discontinuation in patients with CP-CML ASH 2017#](https://reader035.vdocuments.site/reader035/viewer/2022070822/5f25e48d3be37644733aac27/html5/thumbnails/14.jpg)
Cortes, et al. J Clin Oncol 2018;36:231-7
BEFORE 1 yr follow-up: Molecular response
![Page 15: Optimal first-line treatment of chronic phase CMLicksh.org/2018/data/ES02-1_Kyoung_Ha_Kim.pdf · Published clinical studies of TKI discontinuation in patients with CP-CML ASH 2017#](https://reader035.vdocuments.site/reader035/viewer/2022070822/5f25e48d3be37644733aac27/html5/thumbnails/15.jpg)
RERISE 3 yr follow-up:
Cumulative MMR Rates over time
ASH 2017 # 317
![Page 16: Optimal first-line treatment of chronic phase CMLicksh.org/2018/data/ES02-1_Kyoung_Ha_Kim.pdf · Published clinical studies of TKI discontinuation in patients with CP-CML ASH 2017#](https://reader035.vdocuments.site/reader035/viewer/2022070822/5f25e48d3be37644733aac27/html5/thumbnails/16.jpg)
Selecting a frontline treatment
• Efficacy of TKI in first-line clinical trials
• Patient’s age
• Patient’s comorbidities
• TKI toxicity profile
• Adherence
• Risk score
• BCR-ABL transcript type
• Additional chromosomal abnormalities (ACAs)
![Page 17: Optimal first-line treatment of chronic phase CMLicksh.org/2018/data/ES02-1_Kyoung_Ha_Kim.pdf · Published clinical studies of TKI discontinuation in patients with CP-CML ASH 2017#](https://reader035.vdocuments.site/reader035/viewer/2022070822/5f25e48d3be37644733aac27/html5/thumbnails/17.jpg)
Bower et al. J Clin Oncol 2016;34:2851-7
Patient ≤ 50 yrs → Expected survival ≥ 30yrs
Durable CMR → Therapy discontinuation !!!
Elderly patients
Discontinuation → Less important
Swedish Cancer
Registry : 2662 CML pts
![Page 18: Optimal first-line treatment of chronic phase CMLicksh.org/2018/data/ES02-1_Kyoung_Ha_Kim.pdf · Published clinical studies of TKI discontinuation in patients with CP-CML ASH 2017#](https://reader035.vdocuments.site/reader035/viewer/2022070822/5f25e48d3be37644733aac27/html5/thumbnails/18.jpg)
Published clinical studies of TKI discontinuation in patients with CP-CML
ASH 2017# Education
![Page 19: Optimal first-line treatment of chronic phase CMLicksh.org/2018/data/ES02-1_Kyoung_Ha_Kim.pdf · Published clinical studies of TKI discontinuation in patients with CP-CML ASH 2017#](https://reader035.vdocuments.site/reader035/viewer/2022070822/5f25e48d3be37644733aac27/html5/thumbnails/19.jpg)
Selecting a frontline treatment
• Efficacy of TKI in first-line clinical trials
• Patient’s age
• Patient’s comorbidities
• TKI toxicity profile
• Adherence
• Risk score
• BCR-ABL transcript type
• Additional chromosomal abnormalities (ACAs)
![Page 20: Optimal first-line treatment of chronic phase CMLicksh.org/2018/data/ES02-1_Kyoung_Ha_Kim.pdf · Published clinical studies of TKI discontinuation in patients with CP-CML ASH 2017#](https://reader035.vdocuments.site/reader035/viewer/2022070822/5f25e48d3be37644733aac27/html5/thumbnails/20.jpg)
Adverse effects of BCR-ABL1 inhibitors
Pleural/Lung problems
Dasatinib Dasatinib
Imatinib
Nilotinib
Cytopenias
Imatinib
Fluid retention
Nilotinib
Hyperglycemia Skin changes
Imatinib
Nilotinib
PAOD
Nilotinib
Steegmann JL et al., Leuk Lymphoma, 2012; 53:2351-61. Courtesy of Dr DK Kim
![Page 21: Optimal first-line treatment of chronic phase CMLicksh.org/2018/data/ES02-1_Kyoung_Ha_Kim.pdf · Published clinical studies of TKI discontinuation in patients with CP-CML ASH 2017#](https://reader035.vdocuments.site/reader035/viewer/2022070822/5f25e48d3be37644733aac27/html5/thumbnails/21.jpg)
Unique profiles of clinically overt recurrent nonhematologic AEs in
patients with CML treated with BCR/ABL1-targeting TKIs
++, >20% of patients in at least 2 different studies
+, >5% of patients win at least 2 different studies
+/-, 1-5% in at least 1 study
-.<1%
Peter Valent et al. Blood 2015;125(6):901
![Page 22: Optimal first-line treatment of chronic phase CMLicksh.org/2018/data/ES02-1_Kyoung_Ha_Kim.pdf · Published clinical studies of TKI discontinuation in patients with CP-CML ASH 2017#](https://reader035.vdocuments.site/reader035/viewer/2022070822/5f25e48d3be37644733aac27/html5/thumbnails/22.jpg)
Risk factors predisposing for the development of VAEs
Peter Valent et al. Blood 2015;125(6):901
![Page 23: Optimal first-line treatment of chronic phase CMLicksh.org/2018/data/ES02-1_Kyoung_Ha_Kim.pdf · Published clinical studies of TKI discontinuation in patients with CP-CML ASH 2017#](https://reader035.vdocuments.site/reader035/viewer/2022070822/5f25e48d3be37644733aac27/html5/thumbnails/23.jpg)
Risk factors predisposing for the development of pleural effusion
Peter Valent et al. Blood 2015;125(6):901
![Page 24: Optimal first-line treatment of chronic phase CMLicksh.org/2018/data/ES02-1_Kyoung_Ha_Kim.pdf · Published clinical studies of TKI discontinuation in patients with CP-CML ASH 2017#](https://reader035.vdocuments.site/reader035/viewer/2022070822/5f25e48d3be37644733aac27/html5/thumbnails/24.jpg)
Selecting a frontline treatment
• Efficacy of TKI in first-line clinical trials
• Patient’s age
• Patient’s comorbidities
• TKI toxicity profile
• Adherence
• Risk score
• BCR-ABL transcript type
• Additional chromosomal abnormalities (ACAs)
![Page 25: Optimal first-line treatment of chronic phase CMLicksh.org/2018/data/ES02-1_Kyoung_Ha_Kim.pdf · Published clinical studies of TKI discontinuation in patients with CP-CML ASH 2017#](https://reader035.vdocuments.site/reader035/viewer/2022070822/5f25e48d3be37644733aac27/html5/thumbnails/25.jpg)
• adherence rates ↓ response rate ↓ survival rate ↓
Beaumont JL, et al. Blood. 2011;118(21):471 [abstract 1025].
Marin et al. J Clin Oncol. 2010;28(14):2381-2388.
Adherence is the critical factor for response
![Page 26: Optimal first-line treatment of chronic phase CMLicksh.org/2018/data/ES02-1_Kyoung_Ha_Kim.pdf · Published clinical studies of TKI discontinuation in patients with CP-CML ASH 2017#](https://reader035.vdocuments.site/reader035/viewer/2022070822/5f25e48d3be37644733aac27/html5/thumbnails/26.jpg)
Administration of TKI
Imatinib Qd, with a meal
Dasatinib Qd, with no meal
Nilotinib Bid, fasting two hours before and one hour after each dose
Bosutinib Qd, with a meal
Radotinib Bid, fasting two hours before and after each dose
Ponatinib Qd, with or without a meal
![Page 27: Optimal first-line treatment of chronic phase CMLicksh.org/2018/data/ES02-1_Kyoung_Ha_Kim.pdf · Published clinical studies of TKI discontinuation in patients with CP-CML ASH 2017#](https://reader035.vdocuments.site/reader035/viewer/2022070822/5f25e48d3be37644733aac27/html5/thumbnails/27.jpg)
Selecting a frontline treatment
• Efficacy of TKI in first-line clinical trials
• Patient’s age
• Patient’s comorbidities
• TKI toxicity profile
• Adherence
• Risk score
• BCR-ABL transcript type
• Additional chromosomal abnormalities (ACAs)
![Page 28: Optimal first-line treatment of chronic phase CMLicksh.org/2018/data/ES02-1_Kyoung_Ha_Kim.pdf · Published clinical studies of TKI discontinuation in patients with CP-CML ASH 2017#](https://reader035.vdocuments.site/reader035/viewer/2022070822/5f25e48d3be37644733aac27/html5/thumbnails/28.jpg)
Calculation of relative risk
http://www.leukemia-net.org/content/leukemias/cml/cml_score/ http://www.leukemia-net.org/content/leukemias/cml/eutos_score/
SOKAL HASFORD EUTOS
Age 0.116 (age -43.4) 0.666 when age≥50 Non applicable
Spleen (cm below
costal margin, max
distance)
0.0345 (spleen-7.51) 0.042 x spleen 4 × spleen
Platelet (x 109/L) 0.188[(platelet count ÷ 700)2 -
0.563]
1.0956 when platelet
count >1,500
Non applicable
Blood myeloblasts (%) 0.0887 × (myeloblasts - 2.10) 0.0584 blast cells Non applicable
Blood basophils (%)
Non applicable 0.20399 when
basophils >3%
7 × basophils
Blood eosinophils (%) Non applicable 0.0413 × eosinophils Non applicable
Relative risk Exponential of the total Total x 1000 Total
LOW <0.8
≤780
≤87
INTERMEDIATE 0.8-1.2
781-1480 Non applicable
HIGH >1.2 >1480 >87 Sokal JE et al, Blood 1984; 63: 789-799
Hasford J et al, JNTL Cancer Inst 1998; 90: 850-858
Hasford J et al. Blood 2011;118:686-92
![Page 29: Optimal first-line treatment of chronic phase CMLicksh.org/2018/data/ES02-1_Kyoung_Ha_Kim.pdf · Published clinical studies of TKI discontinuation in patients with CP-CML ASH 2017#](https://reader035.vdocuments.site/reader035/viewer/2022070822/5f25e48d3be37644733aac27/html5/thumbnails/29.jpg)
low Int High
16.9-25.6% ↑ 17.3-27.7% ↑ 19.2-21.8% ↑
2G TKI → more beneficial in patients with intermediate or high risk disease
Saglio and Jabbour. Leukemia & Lymphoma 2017
Response according to risk score assessment
![Page 30: Optimal first-line treatment of chronic phase CMLicksh.org/2018/data/ES02-1_Kyoung_Ha_Kim.pdf · Published clinical studies of TKI discontinuation in patients with CP-CML ASH 2017#](https://reader035.vdocuments.site/reader035/viewer/2022070822/5f25e48d3be37644733aac27/html5/thumbnails/30.jpg)
Selecting a frontline treatment
• Efficacy of TKI in first-line clinical trials
• Patient’s age
• Patient’s comorbidities
• TKI toxicity profile
• Adherence
• Risk score
• BCR-ABL transcript type
• Additional chromosomal abnormalities (ACAs)
![Page 31: Optimal first-line treatment of chronic phase CMLicksh.org/2018/data/ES02-1_Kyoung_Ha_Kim.pdf · Published clinical studies of TKI discontinuation in patients with CP-CML ASH 2017#](https://reader035.vdocuments.site/reader035/viewer/2022070822/5f25e48d3be37644733aac27/html5/thumbnails/31.jpg)
Impact of BCR-ABL transcript type on outcome in
patients with chronic-phase CML treated with tyrosine
kinase inhibitors
Jain et al. Blood 2016; 127:1269-75
** two most common transcripts: e13a2 (B2a2) and e14a2 (b3a2)
![Page 32: Optimal first-line treatment of chronic phase CMLicksh.org/2018/data/ES02-1_Kyoung_Ha_Kim.pdf · Published clinical studies of TKI discontinuation in patients with CP-CML ASH 2017#](https://reader035.vdocuments.site/reader035/viewer/2022070822/5f25e48d3be37644733aac27/html5/thumbnails/32.jpg)
Jain et al. Blood 2016; 127:1269-75
b2a2 b3a2
Molecular responses (≤10% or ≤1%) for BCR-ABL at 3 and 6months
according to the type of BCR-ABL transcript (e13a2, e14a2, or both)
![Page 33: Optimal first-line treatment of chronic phase CMLicksh.org/2018/data/ES02-1_Kyoung_Ha_Kim.pdf · Published clinical studies of TKI discontinuation in patients with CP-CML ASH 2017#](https://reader035.vdocuments.site/reader035/viewer/2022070822/5f25e48d3be37644733aac27/html5/thumbnails/33.jpg)
Jain et al. Blood 2016; 127:1269-75
Factors predictive of EFS including the type of BCR-ABL transcripts
![Page 34: Optimal first-line treatment of chronic phase CMLicksh.org/2018/data/ES02-1_Kyoung_Ha_Kim.pdf · Published clinical studies of TKI discontinuation in patients with CP-CML ASH 2017#](https://reader035.vdocuments.site/reader035/viewer/2022070822/5f25e48d3be37644733aac27/html5/thumbnails/34.jpg)
Characteristics of CP-CML patients with major-route ACAs
Fabarius et al. Blood 2011; 118:6760-8
![Page 35: Optimal first-line treatment of chronic phase CMLicksh.org/2018/data/ES02-1_Kyoung_Ha_Kim.pdf · Published clinical studies of TKI discontinuation in patients with CP-CML ASH 2017#](https://reader035.vdocuments.site/reader035/viewer/2022070822/5f25e48d3be37644733aac27/html5/thumbnails/35.jpg)
** Conclusion
Major route ACA at diagnosis are associated with a negative impact on survival
and signify progression to the AP/BP
Fabarius et al. Blood 2011; 118:6760-8
Cumulative incidences of MMR for patients with t(9;22), t(v;22), and
minor- and major-route ACAs
![Page 36: Optimal first-line treatment of chronic phase CMLicksh.org/2018/data/ES02-1_Kyoung_Ha_Kim.pdf · Published clinical studies of TKI discontinuation in patients with CP-CML ASH 2017#](https://reader035.vdocuments.site/reader035/viewer/2022070822/5f25e48d3be37644733aac27/html5/thumbnails/36.jpg)
Conclusions
• A balance between the achievements of an early
response, long-term outcomes, potential AEs, and a
patient’s lifestyle are all key components for successful
therapy.
• Special considerations for patient-TKI pairing include
comorbidities, concomitant medications, age and sex,
risk factors, BCR-ABL1 transcript type and ACAs
![Page 37: Optimal first-line treatment of chronic phase CMLicksh.org/2018/data/ES02-1_Kyoung_Ha_Kim.pdf · Published clinical studies of TKI discontinuation in patients with CP-CML ASH 2017#](https://reader035.vdocuments.site/reader035/viewer/2022070822/5f25e48d3be37644733aac27/html5/thumbnails/37.jpg)
경청해 주셔서 감사합니다.